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BACKGROUND/OBJECTIVES: The present study investigated the hypothesis that a highly pure linear β-1,3-glucan produced 
by Agrobacterium sp. R259 enhances human natural killer (NK) cell activity and suppresses pro-inflammatory cytokines.
SUBJECTS/METHODS: In an eight-week, double-blind, randomized, placebo-controlled clinical trial, 83 healthy adults with white 
blood cell counts of 4,000-8,000 cells/μL were participated and randomly assigned to take two capsules per day containing 
either 350 mg β-1,3-glucan or placebo. Six participants withdrew their study consent or were excluded due to NK cell activity 
levels outside the normal range. NK cell activity and serum levels of immunoglobulin G (IgG) and cytokines, such as interferon 
(IFN)-γ, interleukin (IL)-2, IL-4, IL-6, IL-10, IL-12 and tumor necrosis factor (TNF)-α were measured. 
RESULTS: NK cell activity and the serum levels of IL-10 were significantly higher from baseline to week 8 in the β-glucan 
group compared with the placebo group (P = 0.048, P = 0.029). Consumption of β-1,3-glucan also significantly increased NK 
cell activity compared with placebo after adjusting for smoking and stress status (P = 0.009). In particular, the effect of β-1,3-glucan 
on NK cell activity was greater in participants with severe stress than in those experiencing mild stress. However, the administration 
β-1,3-glucan did not significantly modulate the levels of IFN-γ, IL-2, IL-4, IL-6, IL-12, TNF-α and IgG compared with the placebo. 
CONCLUSION: The results showed that supplementation with bacterial β-1,3-glucan significantly increased NK cell activity without 
causing any adverse effects. Additionally, the beneficial effect of β-1,3-glucan on NK cell activity was greater in participants 
experiencing severe stress.
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INTRODUCTION6)
Natural β-D-glucose polysaccharides, the β-glucans, which 
occur in the cell walls of cereal, fungi, yeast and bacteria, have 
been reported to be a modulator of immune responses [1]. 
Variant forms of β-glucans from different sources have been 
identified, such as bacterial β-glucan structured with only a β
-1,3 linkage, yeast and fungal β-glucans containing a β-1,3 
backbone with 1,6 side branches, and cereal β-glucan with β-1,3 
and β-1,4 backbones [2]. 
β-Glucans have been shown to activate pattern recognition 
receptors expressed on immune cells, such as macrophages, 
dendritic cells, neutrophils and lymphocytes [1,3]. Additionally, 
the enhancement of natural killer (NK) cell activity by β-glucan 
has been reported to play an important role in immune potency 
and to have anti-carcinogenic effects in in vitro and in vivo 
studies [4,5]. The immune stimulation and antitumoral activities 
of these β-glucans have been thought to be caused only by 
the β-1,3-glucans [6]. However, several types of β-1,3-glucans 
from different sources have been shown to result in a variety 
of different immune responses. 
The majority of previous studies have reported on the effects 
of yeast or fungal β-1,3/1,6-glucan on immune responses [7-10]. 
Yeast-derived β-1,3/1,6-glucans increased the serum concentration 
of interleukin (IL)-10 in overweight humans [7]. Mushroom- 
derived β-1,3/1,6-glucans also enhanced IL-8 synthesis in both 
peripheral blood mononuclear cells (PBMC) and polymor-
phonuclear leukocyte cultures from human volunteers [8], 
increased the number of circulating NK cells in athletes [9], and 
increased NK cell activity in healthy adults [10]. However, β
-1,3/1,4-glucans from oats did not alter NK cell activity or the 
levels of plasma cytokines in athletes [11]. 
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Fig. 1. HPLC chromatogram (A) and structure of β-1,3-glucan (B) 
Purified linear β-1,3-glucans extracted from the mushroom 
Cordyceps militaris were reported to have anti-inflammatory 
properties in human monocytic cells; however, the yield of β
-1,3-glucan was only 1.8% in that study [12]. Bacterial linear β
-1,3-glucan has advantages in terms of cost, yield and efficiency, 
compared with β-glucans derived from mushrooms, plants, 
yeasts and fungi [13]. The linear β-1,3-glucan (curdlan) produced 
by Agrobacterium species inhibited cancer progression through 
immune modulation in a mouse model of breast cancer [14], 
and promoted myeloid-derived suppressor cells to differentiate 
into a more mature state in tumor-bearing mice [15]. 
In addition, bacterial linear β-1,3-glucans produced by 
Agrobacterium sp. R259, a mutant strain, increased interferon 
(IFN)-γ production in PBMCs of mice [16], and reversed the 
functional defects of NK cells and excessive immunoglobulin 
(Ig) A production in mice with inflammatory bowel syndrome 
[17]. However, no clinical study has investigated the effects of 
linear β-1,3-glucan produced by Agrobacterium sp. R259 on NK 
cell activity and cytokine concentrations. Therefore, the present 
study investigated the hypothesis that a highly pure β-1,3- 
glucan of low molecular weight (around 17 kDa) produced by 
Agrobacterium sp. R259 enhances NK cell activity and suppresses 
pro-inflammatory cytokines in healthy adults.
SUBJECTS AND METHODS
Study materials
The β-1,3-glucan was prepared by fermentation using 
Agrobacterium sp. R259 (Korean Culture Type Collection, Daejeon, 
Korea; KCTC 10197BP) in sugar medium (Naturence Co., Ltd., 
Gongju City, Korea). After fermentation, β-1,3-glucan was 
separated by centrifugation at 8,000 x g for 30 min, precipitated, 
washed, and spray-dried to obtain purified β-glucan (85%). The 
estimated molecular size of the β-1,3-glucan was approximately 
17~25 kDa, as determined by HPLC analysis (Fig. 1). The 
endotoxin level of the β-1,3-glucan was determined using a 
Limulus Amebocyte Lysate test kit (Pyrogent Plus, Lonza, 
Walkersville, MD, USA), and found to be < 0.07 EU/mL. 
According to prior studies [16,17] on immune responses to 
bacterial β-1,3-glucan, the optimal daily dose of β-1,3-glucan 
was 350 mg. Each capsule of β-1,3-glucan contained 206.0 mg 
β-1,3-glucan powder (as 175.0 mg β-1,3-glucan), 64.0 mg cellulose, 
22.0 mg dextrin, 3.8 mg magnesium stearate, and 4.2 mg silicon 
dioxide; each placebo capsule contained 180.0 mg cellulose, 
112.8 mg dextrin, 3.0 mg magnesium stearate, and 4.2 mg silicon 
dioxide.
Participants
The study participants were recruited via poster and newspaper 
advertisements during September 2014. The inclusion criteria 
for participants were as follows: age between 25 and 70 years 
old, a white blood cell (WBC) count between 4,000-8,000 cells/μL, 
no chronic disease such as hypertension, diabetes and thyroid 
disease, no medical history of myocardial infarction or cerebro-
vascular disease, not pregnant or lactating. The exclusion 
criteria were as follows: any infectious disease, an immune or 
psychiatric disorder, intake any medication or supplements 
regularly within the previous 3 months, a creatinine level ≥ 2 
times the normal upper limit, and an aspartate aminotran-
sferase (AST) or alanine aminotransferase (ALT) level ≥ 3 times 
the normal upper limit. The perception of stress was investigated 
whether in the habitual stress status of the subject. This self- 
reporting of stress using a four-step scale (never, mild, severe 
and very severe) was used previously by Fries et al. [18]. One 
hundred and fifty-six volunteers were screened, and eighty- 
three healthy adults were the participants who met the study 
criteria. All participants were in accordance with the declaration 
of Helsinki, and gave a written informed consent, which was 
approved by the Institutional Review Board of Hanyang 
University (HYI-14-084-1).
Study design 
This study was designed as an eight-week, double-blind, 
randomized controlled clinical trial. Four visits were required 
of participants, including 1 for screening and 3 for the 
intervention study. Participants were interviewed to obtain 
socio-demographic data and medical history, including age, 
marital status, and family history of immune disorders, smoking 
habits, alcohol consumption, physical activity, stress status, 
supplement usage, and medication. Two capsules of β-glucan 
or placebo containing cellulose were provided daily. This study 
was registered with the Clinical Research Information Service 
(KCT0001868).
The three scheduled visits for this clinical trial were conducted 
at the following times after the initial screening: visit 1 (baseline, 
7-10 days post-screening); visit 2 (week 4); and visit 3 (week 
8). Fasting blood and urine samples were collected and stored 
at -20°C until final analysis for study outcomes and a safety 
assessment test. At weeks 4 and 8, compliance was monitored 
by counting the number of remaining capsules.
Participants were informed not to change their usual dietary 
habit and lifestyle, and not to take any health products 
containing β-glucan during the study. To investigate whether 
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Fig. 2. Schematic diagram of study design 
their dietary habits changed, participants were asked about 
their previous day’s food intake using a 24-hr dietary recall at 
visits 2 to 4. These dietary records were analyzed with Can-pro 
4.0 (Computer Aided Analysis Program 4.0 for professionals, 
Korean Society of Nutrition, Seoul, Korea).
Clinical and biochemical measurements
Height was measured using a stadiometer at the baseline visit, 
and weight was measured with participants wearing light 
clothing and without shoes using an Inbody 720 (Biospace 
Corporation, Seoul, Korea). Body mass index (BMI, kg/m2) was 
calculated as weight divided by the square of the body height. 
NK cell activity and cytokines were measured at weeks 0, 4, 
and 8. PBMCs were isolated by density gradient separation, 
resuspended in phosphate-buffered saline, and determined 
using trypan blue solution. NK cell activity was calculated from 
the results of nonradioactive cytotoxicity assay kits (Promega 
Inc., Madison, WI, USA). Effector cells (PBMCs) were seeded in 
96-well plates, with 50 μL of target cells (2×105/mL, K562 cells, 
Korean Cell Line Bank, Seoul, Korea), and incubated for 4 hours 
at 37°C. The ratio of effector:target cells was 100:1, and each 
assay was performed in triplicate. The cytotoxic activity of cells 
was determined using an iMark TM microplate reader (Bio-Rad 
Laboratories, Inc., Hercules, CA, USA) at 490 nm. Cytotoxicity 
was calculated using the following formula:
Cytotoxicity (%) = [(experimental-effector spontaneous-target 
spontaneous)/(target maximum-target spontaneous)] 
x100.
The serum levels of cytokines, including IFN-γ, IL-2, IL-4, IL-6, 
IL-10, IL-12 and tumor necrosis factor (TNF)-α were measured 
using the Luminex system (Bio-Plex 200, Bio-Rad, Korea) on 
multi-analyte panels with a Bio-Plex cytokine assay kit (Bio-Rad 
Laboratories, Inc., Hercules, CA, USA) according to the manufa-
cturer’s protocol. Data analysis was performed with Bio-plex 
Manager 6.1 software (Bio-Rad Laboratories, Inc., Hercules, CA, 
USA). Serum immunoglobulin G (IgG) was measured using a 
turbidimetry immunoassay system (Cobas C501, Roche, Japan) 
with an IGG-2 immunoassay kit (Roche Diagnostics GmbH, 
Mannheim, Germany), and the degree of the turbidity caused by 
the aggregate was determined measuring absorbance at 340 nm. 
Safety assessment
General blood parameters, blood pressure, pulse rate and 
body temperature were measured during each study visit, and 
adverse events and drug usage were also recorded during the 
study. Hematology lab tests, including red blood cell (RBC) 
count, WBC count, hemoglobin, hematocrit, platelet and 
differential leukocyte count, were determined by a Coulter STKS 
hemocytometer (Beckman Coulter Inc., Fullerton, CA, USA). 
Serum were analyzed with a Hitachi 7150 automated analyzer 
(Hitachi Ltd., Tokyo, Japan) for blood chemistry assays, and urine 
were examined with a Clinitek Atlas automated urine chemistry 
analyzer (Siemens Healthcare Diagnostics, NY, USA). Blood 
pressure and pulse rate were measured by an Omron HEM-7051 
device (Omron healthcare, Kyoto, Japan), and body temperature 
was measured using an infrared thermometer (Thermoscan 
IRT-4020, Braun Corporation, Kronberg, Germany).
Randomization
Participants were randomly assigned to an experimental 
group to receive either β-glucan or the placebo using a 
computer-generated randomization program. The sequentially 
numbered packs with either β-glucan or placebo were 
randomly assigned to participants at their first visit. The identity 
codes concealed in sequentially numbered envelopes were 
managed by the study investigators, and monitored by clinical 
research associates (Neonutra Corporation, Seoul, Korea). All 
study investigators and participants remained blinded to the 
identity codes during the study.
Statistical analysis
The primary outcome of this study was the changes in NK 
cell activity between the β-glucan and placebo groups after 
8 weeks. The power calculation was based on the results of 
previous studies [10]. In order to achieve a statistical power of 
80% (P < 0.05, two-tailed test), the required sample size was 
calculated to be 32 in each group. The final required sample 
size was calculated to be 40 in each group, allowing for the 
predicted drop-out rate of 20% during the study [19,20]. 
Statistical analyses were conducted using SAS software, 
version 9.2 (SAS, Inc., Cary, North Carolina, USA). The final results 
from study participants were evaluated using full analysis set 
(FAS). Participants were included if they completed the 8-week 
trial and had taken β-glucan or placebo at least once. The 
continuous variables of the baseline characteristics between the 
β-glucan and placebo groups were compared using an 
independent t-test; categorical variables were compared using 
a Chi-square test or Fisher’s exact test. NK cell activity and 
cytokine concentrations between the two groups from week 
0 to week 4 and week 8 were compared using an ANCOVA 
test after adjusting for smoking and stress status. Statistical 
significance was considered at P < 0.05. All data are presented 
as means ± SDs for continuous variables or as n (%) for 
categorical variables. 
RESULTS
Participant characteristics
Among the eighty-three males and females recruited, forty- 
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β-glucan (n = 40) Placebo (n = 37)
P-value2) P-value3)
Baseline Week 4 Week 8 Baseline Week 4 Week 8
NK cell activity (%)  8.00 ± 13.06 10.06 ± 8.59 12.83 ± 8.06 12.64 ± 14.94 10.42 ± 8.32 10.69 ± 5.89 0.048 0.009
IFN-γ (pg/mL)  0.94 ± 0.73  0.88 ± 0.92  0.84 ± 0.53  0.78 ± 0.36  0.76 ± 0.36  0.79 ± 0.35 0.142 0.667
IL-2 (pg/mL)  1.69 ± 0.35  1.69 ± 0.31  1.74 ± 0.40  1.69 ± 0.39  1.68 ± 0.43  1.70 ± 0.37 0.450 0.177
IL-4 (pg/mL) 21.78 ± 7.59 21.07 ± 8.82 21.32 ± 8.41 23.46 ± 8.52 22.49 ± 8.90 22.48 ± 9.10 0.576 0.259
IL-6 (pg/mL)  2.05 ± 1.00  1.94 ± 0.68  2.00 ± 0.90  1.93 ± 0.81  1.88 ± 0.80  1.84 ± 0.65 0.827 0.856
IL-10 (pg/mL)  1.56 ± 0.51  1.55 ± 0.52  1.69 ± 0.72  1.68 ± 0.52  1.53 ± 0.54  1.57 ± 0.55 0.029 0.094
IL-12 (pg/mL) 20.04 ± 6.51 20.07 ± 6.33 20.19 ± 6.29 21.44 ± 6.96 20.82 ± 7.06 20.82 ± 7.04 0.201 0.152
TNF-α (pg/mL) 12.43 ± 3.99 12.84 ± 5.30 12.04 ± 3.87 12.02 ± 3.99 11.61 ± 5.05 11.78 ± 4.07 0.782 0.196
IgG (g/dL)  1.19 ± 0.20  1.18 ± 0.18  1.19 ± 0.18  1.27 ± 0.18  1.24 ± 1.79  1.29 ± 0.18 0.244 0.329
1) Values are means ± SDs.
2) P-values for differences of changes from baseline between the β-glucan and placebo groups at week 8 were determined by the independent t-test.
3) P-values for difference of changes from baseline between the β-glucan and placebo groups at week 8 were determined by the ANCOVA after adjusting for smoking and 
stress status.
NK cell activity, natural killer cell activity; IFN-γ, interferon-γ; IL-2, interleukin-2; IL-4, interleukin-4; IL-6, interleukin-6; IL-10, interleukin-10; IL-12, interleukin-12; TNF-α, tumor 
necrosis factor-α; IgG, immunoglobulin G.
Table 2. Natural killer cell activity, cytokine, and IgG concentrations between β-glucan and placebo groups1)
β-glucan
(n = 40)
Placebo
(n = 37)
P-value2)
Age (yrs) 33.0 ± 10.0 31.3 ± 9.5 0.447
WBC (103/mm3) 5.78 ± 1.01 5.83 ± 0.98 0.835
Male, n (%) 25 (62.5) 20 (54.1) 0.453
Height (cm) 168.3 ± 7.3 169.3 ± 10.1 0.619
Weight (kg) 67.4 ± 9.9 66.3 ± 13.2 0.674
BMI (kg/m2) 23.7 ± 2.3 23.0 ± 3.7 0.364
Family history of immune disorder, n (%)  6 (15.0)  4 (10.8) 0.739
Smoking, n (%) 10 (25.0)  4 (10.8) 0.039
Drinking, n (%) 27 (67.5) 27 (73.0) 0.597
Exercise, n (%) 19 (47.5) 17 (46.0) 0.891
Stress status, n (%) 0.012
Never  2 (5.0)  1 (2.7)
Mild 18 (45.0) 21 (56.8)
Severe 19 (47.5)  8 (21.6)
Very severe  1 (2.5)  7 (18.9)
1) Values are means ± SDs or numbers of participants (percentage distribution). 
2) P-values were determined by the independent t-test or the Chi-square test or 
Fisher’s exact test between β-glucan and placebo groups.
WBC, white blood cell; BMI, body mass index.
Table 1. Baseline characteristics of β-glucan and placebo groups1)
(A)
(B)
Fig. 3. Changes in NK cell activity (%) and in the levels of IL-10 (pg/mL) 
according to stress status. (A) Changes in NK cell activity (%) from baseline to week 
8 between the β-glucan and placebo groups. (B) Changes in the levels of IL-10 (pg/mL) 
from baseline to week 8 between the β-glucan and placebo groups. P-values were 
determined using an independent t-test.
one participants were randomly assigned to the β-glucan 
group, and forty-two were assigned to the placebo group (Fig. 
2). One participant in the β-glucan group and two in the 
placebo group withdrew their study consent, and three 
participants in the placebo group were excluded due to NK 
cell activity outside the normal range. Compliance was not 
significantly different between the β-glucan and placebo 
groups (94.47 ± 7.65% vs. 92.40 ± 10.65%, P = 0.333). Nutrients 
intake during this study were not observed to be significantly 
different between the two groups, with the exception of 
baseline carbohydrate intake (Supplemental Table 1). However, 
the carbohydrate intake between two groups was not any 
longer significantly different at week 8.
The general characteristics of the participants are shown in 
Table 1. Baseline characteristics, such as age, WBC counts, sex, 
BMI, presence of family history related with immune disorders, 
drinking and exercising were not significantly different between 
the groups. However, there were a higher proportion of current 
smokers and more participants reporting very severe stress in 
the β-glucan group as compared with the placebo group. 
NK cell activity and cytokine concentrations in the β-glucan and 
placebo groups
NK cell activity and cytokine concentrations in the β-glucan 
and placebo groups are shown in Table 2. NK cell activity was 
significantly higher from baseline to week 8 in the β-glucan 
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β-glucan (n = 40)
n (%)
Placebo (n = 37)
n (%)
Dyspepsia  2 (7.69)  1 (4.17)
Stomatitis  0 (0.00)  1 (4.17)
Dental caries and toothache  2 (7.69)  3 (12.50)
Allergic reaction  0 (0.00)  1 (4.17)
Nasopharyngitis 10 (38.46) 11 (45.83)
Rhinitis  2 (7.69)  0 (0.00)
Tinea pedis  1 (3.85)  0 (0.00)
Myalgia  0 (0.00)  1 (4.17)
Headache  4 (15.38)  3 (12.50)
Dysmenorrhoea  2 (7.69)  2 (8.33)
Rhinorrhoea  1 (3.85)  0 (0.00)
Dermatitis  1 (3.85)  0 (0.00)
Table 3. Adverse events frequently occurring in participants taking either β
-glucan or placebo groups
β-glucan (n = 40) Placebo (n = 37)
Baseline Week 8 Baseline Week 8
RBC (106/mm3)  4.63 ± 0.38  4.57 ± 0.39  4.75 ± 0.54  4.67 ± 0.52
WBC (103/mm3)  5.37 ± 1.12  5.72 ± 1.14  5.59 ± 1.24  5.67 ± 1.21
Hemoglobin (g/dL) 14.87 ± 1.27 14.45 ± 1.26 15.08 ± 1.52 14.53 ± 1.66
Hematocrit (%) 43.41 ± 3.69 42.69 ± 3.68 43.79 ± 4.05 42.61 ± 4.66
Platelet (103/mm3) 233.8 ± 34.7 221.2 ± 33.9 239.4 ± 57.0 232.7 ± 49.2
Lymphocyte (%) 38.03 ± 6.02 35.45 ± 6.64 35.76 ± 6.10 36.70 ± 5.82
Monocyte (%)  6.18 ± 1.17  6.48 ± 1.54  6.46 ± 1.41  6.35 ± 1.62
Segmented neutrophil (%) 52.33 ± 6.27 54.80 ± 6.85 54.14 ± 5.70 53.16 ± 5.89
Eosinophil (%)  2.90 ± 1.15  2.38 ± 0.93  2.76 ± 1.04  2.84 ± 1.28
Basophil (%)  0.83 ± 0.55  0.90 ± 0.63  0.92 ± 0.64  0.95 ± 0.62
AST (μ/L) 21.50 ± 5.68 21.98 ± 5.16 20.86 ± 5.32 22.27 ± 5.71
ALT (μ/L) 22.83 ± 9.02 20.35 ± 7.99 22.24 ± 8.20 21.76 ± 9.86
Total protein (g/dL)  7.38 ± 0.362)  7.38 ± 0.38  7.63 ± 0.342)  7.59 ± 0.42
Glucose (mg/dL) 93.75 ± 6.97 90.70 ± 7.44 92.49 ± 7.57 90.54 ± 9.69
Total cholesterol (mg/dL) 196.1 ± 41.9 192.0 ± 35.3 186.6 ± 33.4 185.5 ± 33.3
BUN (mg/dL) 12.11 ± 3.21 12.00 ± 2.70 12.01 ± 2.54 12.15 ± 2.46
Creatinine (mg/dL)  1.02 ± 0.17  0.89 ± 0.13  1.01 ± 0.19  0.92 ± 0.18
Uric acid (mg/dL)  5.86 ± 1.29  5.42 ± 1.17  5.85 ± 1.45  5.55 ± 1.41
Calcium (mg/dL)  9.02 ± 0.262)  9.00 ± 0.25  9.15 ± 0.302)  9.05 ± 0.25
Phosphorus (mg/dL)  4.05 ± 0.252)  3.76 ± 0.313)  3.93 ± 0.272)  3.86 ± 0.383)
Weight (kg) 67.38 ± 9.85 67.82 ± 9.80 66.26 ± 13.22 66.87 ± 13.38
SBP (mmHg) 128.6 ± 11.5 129.2 ± 11.6 129.0 ± 12.2 128.9 ± 13.3
DBP (mmHg) 81.30 ± 9.70 81.00 ± 10.31 80.54 ± 8.91 81.86 ± 9.62
Pulse rate (beats/min) 74.00 ± 10.10 75.18 ± 10.95 76.30 ± 12.46 79.76 ± 11.15
Body temperature (°C) 36.45 ± 0.39 36.17 ± 0.43 36.53 ± 0.40 36.12 ± 0.35
1) Values are means ± SDs.
2) P-values < 0.05 for differences between the β-glucan and placebo groups at baseline were determined by the independent t-test.
3) P-values < 0.05 for differences of changes from baseline between the β-glucan and placebo groups at week 8 were determined by the independent t-test.
RBC, red blood cell; WBC, white blood cell; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BUN, blood urea nitrogen; SBP, systolic blood pressure; DBP, 
diastolic blood pressure.
Table 4. Safety assessments in participants of β-glucan and placebo groups1)
group compared with the placebo group after adjusting for 
smoking and stress status (P = 0.009). The levels of IL-10 were 
also significantly higher from baseline to week 8 in the β-glucan 
group compared with the placebo group (P = 0.029). The levels 
of IFN-γ, IL-2, IL-4, IL-6, IL-12, TNF-α and IgG were not 
significantly different between the β-glucan and placebo 
groups. The immunological effects of β-glucan were assessed 
in the groups with mild stress (never + mild stress) and severe 
stress (severe and very severe stress), as shown in Fig. 3. In 
the group with severe stress, β-glucan significantly increased 
NK cell activity from baseline to week 8; this effect was not 
observed in the group with mild stress.
Safety assessment
Mild adverse events were reported by 17 participants (41.46%, 
26 cases) in the β-glucan group and 17 participants (40.48%, 
24 cases) in the placebo groups; none of the participants 
withdrew due to adverse events (Table 3). All adverse events 
in the two groups were found to be unrelated to intervention. 
The hematological parameters and biochemical variables 
measured during the study period are presented in Table 4. 
Serum levels of calcium and phosphorus were significantly 
different between the β-glucan and placebo groups at baseline. 
In addition, the changes in serum phosphorus from baseline 
to week 8 were significantly different between the β-glucan 
and placebo groups. However, the levels of phosphorus were 
all within a normal range. There were no significant differences 
in any of the other biological parameters between groups. The 
results from all hematologic, biochemical and liver function 
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tests were within in the normal range. Urinary parameters were 
also not significantly different between the groups and were 
within normal range (data not shown). 
DISCUSSION
This randomized, double-blind, placebo-controlled study 
demonstrated that supplementation with purified bacterial 
linear β-1,3-glucan significantly increased NK cell activity, 
compared with a placebo, without any significant adverse 
effects. The effect of β-1,3-glucan was greater in participants 
reporting severe stress than in those experiencing mild stress.
Previous studies have consistently reported that suppleme-
ntation with β-1,3/1,6-glucans from yeast or mushrooms 
activated NK cells in mice with cancer [21] and in healthy adults 
[10], and prevented reductions in NK cell activity and counts 
during the recovery period after intensive training [22]. Although 
β-1,3/1,6-glucans have immunological and anticarcinogenic 
effects, the use of yeast, mushrooms or natural products as a 
source could be associated with problems such as low yield 
and the requirement for more expensive and complicated 
processes for purification [12]. Utilization of bacterial β-1,3- 
glucan could solve these problems, and recent studies have 
confirmed that bacterial linear β-1,3-glucan also modulated the 
immune response in in vitro [14,16] and in vivo studies [17]. 
Wu et al. [14] reported that bacterial linear β-1,3-glucan 
(curdlan) produced by Agrobacterium species inhibited the 
progression of human breast cancer by preventing the generation 
of pro-tumor iTh2 cells. Shim et al. [16] reported that bacterial 
β-1,3-glucan from a mutant strain of Agrobacterium species 
increased IFN-γ production in PBMCs of mice. Lee et al. [17] 
also showed that the linear β-1,3-glucan produced by a mutant 
strain of Agrobacterium species prevented the progression of 
dextran sulfate sodium (DSS)-induced inflammatory bowel disease 
by recovering the reduction in Tregs, the functional defect of 
NK cells and the excessive IgA production in mice. In agreement 
with the previous results, our purified bacterial β-1,3-glucan 
could modulate the immune response by enhancing NK cell 
activities in humans. 
In particular, the present study showed that the effect of β
-glucan on NK cell activity was greater in participants with severe 
stress as compared with those with mild stress. Chronic stress 
had been reported to be associated with suppressed cellular 
immunity [23], and with both pro-inflammatory and anti- 
inflammatory cytokines [24]. Moreover, psychological stress has 
been suggested to reduce NK cell activity through the increased 
production of circulating glucocorticoid [25]. The results of the 
present study suggest that administration of β-1,3-glucan could 
prevent the reduction of immune responses caused by stress.
In the present study, bacterial β-1,3-glucan significantly 
increased the serum level of IL-10, which is an anti-inflammatory 
cytokine that acts as a negative feedback regulator of diverse 
immune responses in preventing inflammatory and autoimmune 
pathologies [26]. The effect of a β-glucan on IL-10 concent-
rations has been reported for the role of Dectin-1, a receptor 
of β-1,3-glucan expressed on NK cells [7,27,28]. The activation 
of NF-κB by β-1,3-glucans leads to the release of cytokines, 
including IL-12, IL-6, TNF-α and IL-10 [1,29]. Supplementation 
with yeast-β-1,3/1,6-glucans increased plasma levels of the 
anti-inflammatory cytokine IL-10 mRNA in adipose tissue in 
overweight to obese subjects with moderately elevated C-reactive 
protein (CRP) levels [7]. In addition, curdlan (a linear bacterial 
β-1-3-glucan) has been suggested to induce IL-10 producing 
CD4(+) T cells and inhibit the development of eosinophilic 
airway inflammation [27]. As a result of previous studies, it is 
likely that β-1,3-glucan could enhance the immune response 
against pathogens by activating NK cells, and control the 
pro-inflammatory cytokines by increasing IL-10 secretion. 
Therefore, β-1,3-glucan is considered to play a regulatory role 
between the pro-inflammatory and anti-inflammatory cytokines.  
In contrast to previous studies, the present study showed that 
bacterial linear β-1,3-glucan had no significant effect on the 
other pro-inflammatory cytokines, such as IFN-γ, IL-2, IL-4, IL-6, 
IL-12, TNF-α and IgG. In particular, no effect was seen on IFN-γ, 
a well-known pro-inflammatory cytokine produced predominantly 
by NK cells as part of the innate immune response, and 
associated with autoimmune diseases [30]. In addition to NK 
cell activity, IFN- γ production in human PBMC was induced 
by IL-12 [31], and was also secreted by activated T cells [32]. 
Cooper et al. [33] reported that IFN- γ was primarily produced 
by CD56bright NK cell subsets, which had the capacity to produce 
abundant cytokines. However, the majority of this cytotoxic 
response in NK cells was induced by CD56dim NK cell subsets, 
which comprise 90% of human NK cells and produce fewer 
cytokines compared to CD56bright NK cell subsets [33]. Thus, 
changes in IFN- γ may be not accompanied by increasing NK 
cell activity in healthy participants. IL-10 is a potent regulator 
of anti-inflammatory immune responses and, hence, is considered 
to be a down-regulator of pro-inflammatory cytokine production 
by Th1 cells and macrophages [34,35]. Therefore, the regulation 
of IL-10 could affect the concentrations of pro-inflammatory 
cytokines, such as IL-12 and TNF-α. Inconsistent results could 
be also due to the source, branches and purity of β-glucan. 
This study has a few limitations. Psychological stress and 
smoking could be confounding factors on immune responses 
[25,36]. In our study there were significant differences between 
the two groups with respect to these two factors. To minimize 
bias, the statistical analyses were conducted after adjustment 
for stress status and smoking. In addition, we did not measure 
whether participant stress status changed during the study 
period. Another limitation was that NK cell counts and other 
functional properties of NK cells, such as IL-17A, MIP-1α or MIP-1
β, and activation of NK cell receptors (CD94 or KIRs), were not 
investigated in this study.
This present study is the first randomized, double-blind, 
placebo-controlled study to suggest that the administration of 
Agrobacterium species-derived bacterial β-1,3-glucan significantly 
increases NK cell activity in healthy adults without causing 
significant adverse effects. Future clinical trials will be needed 
to confirm the immune responses of patients with cancer or 
chronic stress to bacterial linear β-1,3-glucan.
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